Palbociclib

Breast Cancer

Hoffmann-La RocheSmall moleculePhase 4 / ApprovedActive

BB

71/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 75/ 100
Competitive Position: 59/ 100

Competitive context

848 Active assets in the Breast Cancer cohort.

Asset / Sponsor	Phase	Rating
Darolutamide Vandana Abramson	Phase 2	BBB
Pertuzumab SWOG Cancer Research Network	Phase 4	BB
Trastuzumab Duocarmazine Byondis B.V.	Phase 3	BB
Goserelin TerSera Therapeutics LLC	Phase 4	BB
Ribociclib National Cancer Institute (NCI)	Phase 4	BB

View all 50 →

Same molecule, other indications

Palbociclib is also rated in:

Her2-receptor negative breast cancerActive

BBB

Indicative · Phase 2

75 / 100

hormone receptor-positive breast cancerActive

BBB

Indicative · Phase 3

73 / 100

ovarian carcinomaActive

BB

Indicative · Phase 4

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.